Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Eligible for screening study DCP 001
Occupational Report & Pregnancy Report consent forms available upon request. Please contact Amber Boerner, email@example.com or 406-969-6067, for the consents and for any questions.
S1803 is temporarily closed to accrual, effective March 29, 2023, at 12pm Pacific Time.